C-RFCNElixirgen Therapeutics
ZSCAN4, telomere elongation, mRNA
repairingcell therapy
Loading
Загрузка раздела...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-RFCN
C-RFCNC-RFCNZSCAN4, telomere elongation, mRNA
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Elixirgen Therapeutics' Aki Ko joins Erin Harris to detail the company's Bobcat mRNA™ therapeutic and how it differs from traditional exon-skipping drugs and AAV-microdystrophin in treating DMD. Regarding delivery, Ko explains the advantage of the mRNA approach over the AAV approach. -- #celltherapy #genetherapy Subscribe to the podcast! Apple - https://podcasts.apple.com/us/podcast/cell-gene-the-podcast/id1574496063 Spotify - https://open.spotify.com/show/78NSjRuHndVhI5VHWWAMya YouTube - https://music.youtube.com/playlist?list=PLFXsCNKV78rWyuxay7hXQFo0rVyAXAdwX
Aki Ko, of Elixirgen Therapeutics, spoke about the company's development plan to potentially go beyond the investigational new drug application for Bobcat mRNA at the 2024 MDA conference. Read more: https://www.neurologylive.com/view/neurovoices-aki-ko-mrna-therapeutics-duchenne-muscular-dystrophy View more MDA content: https://www.neurologylive.com/conferences/mda
Aki Ko, Chief Executive Officer and co-founder of Elixirgen Therapeutics, discusses treatment advances in telomere biology disorders. Telomere biology disorders are a group of conditions that occur when patients have premature or faster shortening of telomeres due to genetic mutations. This can cause impaired function of many organ systems over time, most commonly affecting bone marrow. Symptoms of telomere biology disorders vary but commonly include: - Slow creation of blood cells - Abnormal pigmentation - Eye and/or dental abnormalities - Esophageal and/or urethral stenosis - Avascular necrosis of femur and/or humerus - Osteopenia - Pulmonary fibrosis - Liver disease As Mr. Ko explains, currently, these disorders are mainly treated with hematopoietic stem cell transplants. However, this treatment poses challenges such as donor matching, preconditioning, and immunosuppression. EXG-34217 is an autologous cell therapy that addresses the root cause in the telomere biology disorders.
This is a long-term rollover follow-up study for Phase I/II study (Protocol EXG-US-01).
This is a Phase I/II, open label, single center study to assess the safety and tolerability of EXG34217 in bone marrow failure patients with telomere biology disorders.
Gene therapy advances for hearing and Parkinson's | Sam Gibbons posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree t … cy of the 3e13 vg/mL unilateral dose. Why this is interesting (to me): 1. Novel application for AAV: AAV's packaging limit (4.7 kb) often constrains therapeutic design. The dual AAV strategy expands this boundary, enabling delivery of larger or more complex gene cassettes. 2. Potentially safer and broader reach: The local injection approach demonstrated good tolerability and efficacy even in patients with pre-existing antibodies against AAV, potentially opening access to a br
%PDF-1.6 %���� 1861 0 obj > endobj 1890 0 obj >/Filter/FlateDecode/ID[ ]/Index[1861 52]/Info 1860 0 R/Length 133/Prev 1889535/Root 1862 0 R/Size 1913/Type/XRef/W[1 3 1]>>stream h�bbd```b``g���@$� �d�����HfA�t��_f˂�� ���s`R�l&w4�,��"�`���H~ �fx ,R�+"��$�9��l ���q&F��`w20�����7��� endstream endobj startxref 0 %%EOF 1912 0 obj >stream h��U�O�U?�>}۠t���gZ�\ ��D�Yq4��h��0?�1;F��dy�yf�T_�E��`@ ��d1E��u$�_R7B\Ф ���x�}���?�I�������9�6�@�f�����"hp�r� �Y uC �m8$R��h�D�b,$G�7%)�����*;� 'S��-ǟg�A��2�ތ24xآF�K9��+x �,������0����� �Cx �I.&�(]��u��Yi�òt�0+W�(��Wa … 22:51+01:00 2022-03-07T18:22:50+01:00 2022-03-07T18:22:51+01:00 65535 1164 1214 application/pdf Figure 1 xmp.did:4baffd63-c5cd-4c1a-806f-2a656a0af85c uuid:2667c2d4-66c8-d94b-8d96-447c614a580a xmp.did:4baffd63-c5cd-4c1a-806f-2a656a0af85c proof:pdf saved xmp.iid:4baffd63-c5cd-4c1a-806f-2a656a0af85c 2022-02-16T14:53:40+01:00 Adobe Illustrator 26.0 (Macintosh) / EmbedByReference /Users/design_mac4/Desktop/RNA-2.jpg EmbedByReference /Users/design_mac4/Desktop/Figure 1-2.jpg /Users … sh) 2022-02-17T13:57:47+01:00 2022-02-17T13:57:47+01:00 Adobe PDF library 16.03 application/pdf Figure 2 xmp.did:7f8b68c4-6599-46d7-93f6-3f5d8183d2a7 uuid:f4482156-ea09-5249-b9e2-a15e3f3a886a uuid:e38e39c3-e841-a14a-a68e-32783838a9a3 proof:pdf uuid:c69f7381-0fac-7b48-8ea7-4dc402a2157d uuid:e38e39c3-e841-a14a-a68e-32783838a9a3 uuid:e38e39c3-e841-a14a-a68e-32783838a9a3 saved xmp.iid:7f8b68c4-6599-46d7-93f6-3f5d8183d2a7 2022-02-14T13:17:23+01:00 Adobe Illustrator 26.0 (Macintosh … sh) 2022-02-17T14:43:35+01:00 2022-02-17T14:43:35+01:00 Adobe PDF library 16.03 application/pdf Figure 3 1 False False 140.606331 67.197798 Millimeters HelveticaNeueLTStd-Roman Helvetica Neue LT Std 55 Roman Open Type Version 2.020;PS 002.000;hotconv 1.0.50;makeotf.lib2.0.16970 False HelveticaNeueLTStd-Roman.otf Cyan Magenta Yellow Black Groupe de nuances par défaut 0 Document AIRobin xmp.did:eea98c29-bfd6-4db5-b566-a48e75c351c4 uuid:620950ab-c950-9f43-88c0-69599178d521 xmp.d … 420ba6-d021-42e8-afca-0e9118bd6dad xmp.iid:c4420ba6-d021-42e8-afca-0e9118bd6dad application/pdf Figure 4 AIRobin Document endstream endobj 56 0 obj >stream ����Adobed��� ��j��[M��
Login | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib market China CAR T Alzheimer'
ElevateBio - aVenture Company Research Home Research Loading aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions. aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showca
Process Steps in Cell Therapy Manufacturing Get more Cell & Gene insight with our FREE newsletter sign me up Log In or Subscribe Explore CGT Production Vectors Cell Therapy Manufacturing Gene Therapy Manufacturing Formulation Fill-Finish Cold Chain Management Quality Control & Assurance Find Suppliers Clinical Trial Services Manufacturing Regulatory Supply Chain Outsourcing Translational Research Watch Now STREAM Video Channel Cell & Gene Live Cell & Gene: The Podcast Cell & Gene Tech Expo Our Communities Advancing RNA Bioprocess Online Clinical Leader Clinical Supply Leade
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
FDA Approves Elixirgen Therapeutics IND Application for Therapy for Telomere Biology Disorders with Bone Marrow Failure • Elixirgen Therapeutics Skip to content Science Clinical Trial About News Contact FDA Approves Elixirgen Therapeutics IND Application for Therapy for Telomere Biology Disorders with Bone Marrow Failure June 4, 2020 BALTIMORE, June 4, 2020 /PRNewswire/ — Elixirgen Therapeutics, Inc., a Baltimore-based biotechnology company focused on the discovery, development, and commercialization of therapies for genetic diseases and vaccines, received confirmation from the U.S … U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) application for its lead candidate, EXG4217, was approved on May 23, 2020. EXG34217 is an autologous cell therapy for telomere biology disorders with bone marrow failure. The FDA’s approval allows Elixirgen Therapeutics to proceed with its planned Phase I/II, open label, single center clinical trial to assess the safety and tolerability of EXG34217 at Cincinnati Children’s Hospital Med … ttps://www.prnewswire.com/news-releases/fda-approves-elixirgen-therapeutics-ind-application-for-therapy-for-telomere-biology-disorders-with-bone-marrow-failure-301070733.html Top Science About News We develop life-changing therapies, focusing on treatment of rare diseases and aging-associated diseases using our cutting-edge technologies. Headquarters 855 N Wolfe St, Suite 624 Baltimore, MD 21205 (443) 451-5300 Contact Us Science Clinical Trial About News Contact Site Created
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
LINK-J Symposium "The Frontiers of Drug Discovery" | Events | LINK-J LINK-J JP ／ EN Contact us Menu Close FAQ Subscribe to LINK-J Event News JP ／ EN Contact us Login My Page Sign up Events Events LINK-J Events/LINK-J Supported Events Special Member Events Co-sponsorship Past Events Event Reports LINK-J Events/LINK-J Supported Events Special Member Events Exhibitions Programs Out of Box Consulting Room {t("gnav.programs.program")} --> What's "LINK-BioBAY TOKYO"？ Interviews & Blogs Interviews & Blogs Supporter Interviews What’s in Nihonbashi LINK-J Staff Blog Star … ity Special Members List of Special Members About Special Membership Membership Application Facilities Lounges and Conference rooms Offices and Laboratory Access FAQ Subscribe to LINK-J Event News Close Events Events LINK-J Events/LINK-J Supported Events Special Member Events Co-sponsorship Past Events Event Reports LINK-J Events/LINK-J Supported Events Special Member Events Exhibitions Programs Out of Box Consulting Room {t("gnav.programs.program")} --> What's "LINK … ity Special Members List of Special Members About Special Membership Membership Application Facilities Lounges and Conference rooms Offices and Laboratory Access HOME Events LINK-J Symposium "The Frontiers of Drug Discovery" Login My Page Sign up Events Event Date: Fri, June 18, 2021 Pharmaceuticals Cellular Medicine Frontier of Drug Discovery LINK-J Symposium "The Frontiers of Drug Discovery" Important: Please be informed that we have decided to hold the … ademia and industry as speakers to discuss the status of research and practical application of notable modalities such as AI drug discovery, genome editing, cellular medicine, and RNA medicine. In the panel discussion, all the speakers will gather together to deliver heated discussions. *English Simultaneous interpretation is available on the Zoom webinar. Date : Fri, June 18, 2021 1:00pm-4:30pm (JST) Venue : Online (Zoom webinar) Registration (Opens an external site) Registr … 13:40-14:00 “Development of universal T cell medicine produced from iPS cells -Application to cancer immunotherapy and treatment of viral infection-“ Prof. Hiroshi Kawamoto (Professor, Laboratory of Immunology, Institute for Frontier Life and Medical Sciences, Kyoto University) 14:00-14:20 “Exploring the Potential of Pan-Coronavirus Vaccines wit
Start - HEALTH CAPTAINS INSTITUTE Skip to main content News Events Join Club Store Donate Login INSTITUTE FACULTY DEVISIONS HEALTHY LONGEVITY BLUE ZONES ONE HEALTH Toggle Menu INSTITUTE LEADERSHIP PATRONAGE TRUSTEES PRESIDENT CHAIRS PROGRAM COMMITEES INSTITUTE COLLEGE NAVIGATION MEDICINE 4.0 CARE 4.0 HEALTH 4.0 INSTITUTE FACULTY COLLEGE FACULTY INSTITUTE COOKBOOK VISION & MISSION SICKCARE HEALTHCARE LIFECARE FACULTY MEDICAL BOARD ADVISORY BOARD FACULTY TRUSTEES AMBASSADORS DEVISIONS DEVISIONS BUSINESS DEVELOPEMENT STRATEGY STUDIES COMPETITIVE STUDIES CONVERGENCE STUDIES SYNCHRONIZATION ST … a comprehensive longevity strategy that connects scientific discovery, medical application, and economic sustainability—advancing a future where more people live longer in good health. Read More Divisions Overview DIVISIONS OVERVIEW DEVISIONS BUSINESS DEVELOPEMENT… Division Overview “The challenges are too big for any one single organization.” Guided by this shared understanding, THE HEALTH CAPTAINS INSTITUTE serves as a dynamic think-and-do-tank platform for interdis
@teamtelomere.bsky.social on Bluesky JavaScript Required This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is. Learn more about Bluesky at bsky.social and atproto.com . Profile Team Telomere teamtelomere.bsky.social did:plc:tgqnoullhf7inaa3563zefud Nonprofit organization International advocacy for those treating, researching, and affected by Telomere Biology Disorder. #TeamTelomere #DyskeratosisCongenita
Our Science Therapeutic Areas Duchenne Hunter Syndrome EGPA Scientific Approach Exon-Skipping Gene Therapy Selective JAK1 Inhibition Pipeline & Products Products Clinical Trials Resources Education Press Releases Who We Are Our Team Partnership Careers Corporate Culture Contact Us Building healthier futures powered by thoughtful science We are a highly focused, research-driven biopharmaceutical company working in rare diseases. We're exploring the potential of cutting-edge science as a subsidiary of Nippon Shinyaku Co., Ltd. In Japan. Learn more Advancing rare disease research Inspired by … Genetic testing can identify which exons are affected and if this approach may apply. Learn more: https://ow.ly/b9Ux50YB63L #Duchenne #NSPharma https://x.com/NSPharmaInc/status/2038916684778545393/photo/1 NS Pharma @nspharmainc · 27 Mar We’re looking forward to this upcoming community event and the chance to engage in meaningful conversations around #RareDisease care. Listening, learning and sharing perspectives helps move progress forward. We look forward to connecti
Session Detail Skip to content Oct. 28 - 30, 2026 COEX, Seoul English English Korean BIX Sponsor/Booth Inquiry", "Button URL": "https://www.bioplusinterphex.co.kr/en-us/bixinquiry.html", "Button Position": "header" }' data-mixpanel-event='{ "click": "Button Interacted" }' data-rxtag="button" target="_blank"> >BIX Sponsor/Booth Inquiry HOME CONFERENCE AT A GLANCE Conference Sessions Speaker Directory Session Posters EXHIBITOR Exhibiting Information How to Exhibit Sponsorship Program Promotion Items Overseas Contacts VISITOR Visiting Information How to Visit BIX Exhibitor
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
LB: Development of mRNA Therapeutic Delivering Full-length dystrophin for Duchenne Muscular Dystrophy - MDA Clinical & Scientific Conference 2026 and tags on every page of your site. --> Register Now --> Home MDA Conference 2026 Registration Rates Agenda Location & Venue Our Sponsors CE Media Information Sponsorships & Exhibits Sponsorship Levels Event Sponsorships Marketing Sponsorships Exhibit Information Patient Advocacy Pavilion Abstracts 2026 Abstract Guidelines 2026 Abstract Library 2025 Abstract Library 2024 Abstract Library 2023 Abstract Library 2026 On-Demand Conference … Demand Conference About Us About The MDA Conference About MDA Awards MDA Legacy Award for Achievement in Clinical Research The MDA Donavon Decker Community Impact in Research Award MDA Research Momentum Award Future Conferences Contact Us Home MDA Conference 2026 Registration Rates Agenda Location & Venue Our Sponsors CE Media Information Sponsorships & Exhibits Sponsorship Levels Event Sponsorships Marketing Sponsorships Exhibit Information Patient Advocacy Pavilio … Demand Conference About Us About The MDA Conference About MDA Awards MDA Legacy Award for Achievement in Clinical Research The MDA Donavon Decker Community Impact in Research Award MDA Research Momentum Award Future Conferences Contact Us LB: Development of mRNA Therapeutic Delivering Full-length dystrophin for Duchenne Muscular Dystrophy Topic: Pre-Clinical Research Poster Number: T428 Author(s): Minoru Ko, MD, PhD, Elixirgen Therapeutics, Inc., Tomokazu Amano, PhD, Elixirge
Cell 2025 Explore our brands Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. Events In-Person & Online Events Pivotal moments where high-level industry experts and thought leaders come together for focused knowledge sharing and unparalleled networking opportunities. Advanced Analytical Strategies for NextGen Antibodies 17 Sep 2026 | BST (UTC+1) Cell 2026 12 - 13 Nov 2026 | London, UK NextGen Biomed 2027 18 - 19 Mar 2027 | London, UK … ssing Sponsor Cell 2025 Overview What to Expect Speakers Sponsors Start-Up Zone Award Plan Your Visit Overview Cell & Gene Therapy Manufacturing Advanced Therapy Development Cell Culture & Bioprocessing Welcome to Cell 2025 , Oxford Global’s flagship event bringing together leaders from pharma, biotech, academia, and regulatory institutions across the entire cell culture and cell & gene therapy value chain. From discovery and development to manufacturing, supply c … Research Director, Bioarchitech 180 papers. He was awarded the Leonidas Zervas Award of the European Peptide Society in 2012 and the Max Bergmann Medal by the Max-Bergmann-Kreis in 2022. His research covers topics at the interface between synthetic chemistry, biology, biophysics, medicinal chemistry, and nanobioscience. He currently serves as president of the European Peptide Society."> Knud Jørgen Jensen Professor, Copenhagen University Kuda Muchandibaya Lecturer for Supply … n academia and industry. He has won numerous awards, the latest being the Bader Prize by The Royal Society of Chemistry in 2023 and Fellow of the Royal Society of Edinburgh in 2024. Vendrell currently co-heads the IRR Chemistry Hub at the College of Medicine in Edinburgh as one of the first global hubs for collaborative non-siloed research to catalyse innovation in medical sciences and accelerate translational outputs. Group website: www.dynafluors.co.uk"> Marc Vendrell Escob … of results and pride in the insights our customers achieve. More than 35 Nobel Prize winners among more than 500,000 customers worldwide are proof of that success. Together, we are making improvements in life possible. Discover more at http://www.qiagen.com. Visit Website Sartorius Lab Instruments GmbH & Co. KG Silver Sponsor Sartorius is a
Elixirgen Therapeutics Appoints Jeffrey L. Cleland, Ph.D., to Board of Directors • Elixirgen Therapeutics Skip to content Science Clinical Trial About News Contact Elixirgen Therapeutics Appoints Jeffrey L. Cleland, Ph.D., to Board of Directors December 21, 2022 BALTIMORE, Dec. 21, 2022 — Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies using its controllable self-replicating RNA (c-srRNA) platform, today announced the appointment of Jeffrey L. Cleland, Ph.D., to the Board of Directors to s
Team Telomere - Team Telomere Scientific Summit 2026 Log In Team Telomere Scientific Summit 2026 July 7, 2026 @ 8:00AM — July 10, 2026 @ 4:00PM Pacific Time (US & Canada) Add to Calendar Share: Contact [email protected] with questions. A big thank you to our sponsors! River Guide Elixirgen Therapeutics Compass Sean Tully In-person Exhibit Boehringer Ingelheim Pharmaceuticals, Inc. Fly Reel Cohen Children Medical Center The Scientific Networking Event Suneet Agarwal Privacy Policy Ticket Details Price Quantity VIRTUAL Summit Ticket Available For 5 More Days! Includes 2 full days o … 175 0 1 2 3 4 5 6 7 8 9 10+ Summit Registration and Community Celebration & Award Ceremony Ticket 0 tickets left! $625 Sold Out! Trainee Summit Registration and Community Celebration & Award Ceremony Ticket 0 tickets left! Trainees include students, residents, fellows, and postdoctoral researchers currently in academic or clinical training programs. $475 Sold Out! Guest Ticket (0 to 18 years) 0 tickets left! For guests of Scientific Summit attendees. Covers opening se … ession & Wednesday and Thursday evening programming. $250 Sold Out! " type="submit">Purchase Sponsor Our Event Support us with a donation. Donate × Make a Donation × Sponsor our event Learn about our sponsorship levels and choose the one that fits. North Star Available For 8 More Days! $40,000 North Star Level includes: - 4 event tickets - 8 seats at the Boots & Genes Celebration Dinner - 2 exhibit booths - Logo recognition on the conference program - Logo … on Attendee Abstract Book $2,000 The Scientific Networking Event $2,000 " type="submit">Sponsor
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Press Release Distribution and Management Accessibility: Skip TopNav Latest News and Press Releases Want to stay updated on the latest news? Sign into Reader Account Create Reader Account June 26, 2026 06:23 ET | Source: Elixirgen Therapeutics, Inc. Elixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy BALTIMORE, June 26, 2026 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company developing treatments for rare diseases and aging-associated diseases
Elixirgen Therapeutics, Inc. | Institution outputs | Nature Index Skip to main content Advertisement Search Main Navigation Home News News home News Comment Data insights Dataviz Careers Q+A Archive Current Index Institution rankings Institution benchmarking Institution collaboration Country/territory rankings Country/territory benchmarking Country/territory collaboration Data visualizations Articles Research highlights Topics Topic explorer Nature Index topics Leading institutions by topic Leading countries/territories by topic Research leaders Research leaders home 2026 Research Leaders 2025 … environmental sciences — Physical sciences Social sciences Nature & Science Apply Count: 0 Share: 0.00 Article ‘Count’ and ‘Share’ for Elixirgen Therapeutics, Inc. based on listed parameters only. According to the parameters selected above, there are no articles from Elixirgen Therapeutics, Inc. from 1 March 2025 - 28 February 2026. Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International
#telomerebiologydisorder #dyskeratosiscongenita #tbd #raredisease #chronicillness | Team Telomere LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to
How Elixirgen Manufactures Hematopoietic Stem Cells At The Bedside | Elixirgen Therapeutics, Inc. LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to
Elixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy Something went wrong Skip to navigation Skip to main content Skip to right column Yahoo Finance News Finance Sport More News Today's news World UK Weather Politics Science & Tech Lifestyle Health & Wellness Relationships Parenting Entertainment TV Reality TV Movies Celebrity Music Finance My portfolio Watchlists Markets News Screeners Industries Crypto Bank of England Property Top stocks Work and management Brexit Sport Premier … onverter Crypto Stocks: Losers Screeners Saved Screeners Equity Screener Mutual Fund Screener ETF Screener Features Behind The Brand Work & Management ... UK markets closed UK UK US Markets Europe Markets Asia Markets Cryptocurrencies Rates Commodities Currencies UK markets closed FTSE 100 10,508.02 -21.87 -0.21% GBP/USD 1.3198 +0.0001 +0.00% GBP/EUR 1.1589 -0.0008 -0.07% FTSE 250 23,147.19 -14.22 -0.06% AIM 770.35 -1.57 -0.20% GOLD FUTURES 4,103.00 +55.40 +1.37% ADVERTIS
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
Elixirgen Therapeutics Enters Memorandum of Understanding with Hitachi Global Life Solutions for the Development of Micro GMP Suites for Cell Therapy Administration • Elixirgen Therapeutics Skip to content Science Clinical Trial About News Contact Elixirgen Therapeutics Enters Memorandum of Understanding with Hitachi Global Life Solutions for the Development of Micro GMP Suites for Cell Therapy Administration January 26, 2023 BALTIMORE, January 26, 2023 – Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of th
Participating Companies --> --> --> 3 days in-person. 2 days virtually. January 8–10, 2024 | San Francisco, CA, January 16–17, 2024 | Virtual Menu Home What's On? Agenda Presenting Companies Partnering Opportunities Plan Your Visit Register Now Close Book Now Home What's On? Agenda Presenting Companies Partnering Opportunities Plan Your Visit PARTICIPATING COMPANIES Companies participating at Biotech Showcase 2024 Participating Companies --> Filter Filters Close Search Filters Formats Keynote --> Categories View All Participating Companies Presenting companies Investors Irene Abrams, Animal He … United States Body Vision Medical China BOHE Angel Fund Canada Bold Therapeutics Inc. United States Bonaventure Equity, LLC United States Bond Biosciences, Inc. United States Boom Capital South Korea Boryung Co., Ltd. United States Boston Harbor Angels France Bpifrance Netherlands Brabant Development Agency (BOM) United States Brace Pharma &nbs … cal Angel Network China Chengdu Guanghua Wutong Equity Investment Fund Management Co.,Ltd United States Chiesi Ventures Australia Children's Medical Research Institute Canada Chimeric Therapeutics Limited United States Chimeron Bio United States China Daily USA United States Chrysalis BioTherapeutics, Inc. Ireland Chrysea Limited France Cilcare United States Cincinnati Children's … s United States clock.bio United States Cloudstone Venture Fund, L.P. Japan CLOVERNA, Inc. Australia CMAX Clinical Research United States Coagulant Therapeutics United States Coast Bioventures LLC Canada Cobionix United States Cobro Ventures United States Codon Capital China Codone Biotech United States Coeurative, Inc. United States Cogn … p; United Kingdom DeBere Switzerland Debiopharm Innovation Fund SA United States Decheng Capital United States DeckTherapeutics, Inc. Canada Deep Genomics United States DeepCure United Kingdom DeepMirror United States Deerfield United States Defand Therapeu
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Shauna Callahan - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Engage Executives. Unlock Deals. ExecAtlas delivers real-time insight into who-knows-who, paving the way for warm introductions that create opportunities. Search for an Executive Trusted by Industry Leaders Trusted by Industry Leaders Featured Profile Shauna Callahan Board Member at ELIXIRGEN THERAPEUTICS, INC. Shauna Callahan 's Executive Work History Current Board Member , Board Member Equilar on 11/13/2025 ELIXIRGEN THERAPEUTICS, INC. Past To view Shauna Callahan's complete executive work history,
%PDF-1.6 %���� 2815 0 obj > endobj xref 2815 159 0000000017 00000 n 0000003656 00000 n 0000008968 00000 n 0000010219 00000 n 0000010247 00000 n 0000010386 00000 n 0000010539 00000 n 0000010682 00000 n 0000010835 00000 n 0000010988 00000 n 0000011126 00000 n 0000011268 00000 n 0000011352 00000 n 0000011379 00000 n 0000011766 00000 n 0000011934 00000 n 0000012068 00000 n 0000012160 00000 n 0000012252 00000 n 0000012349 00000 n 0000012502 00000 n 0000012641 00000 n 0000012782 00000 n 0000012935 00000 n 0000013103 00000 n 0000013220 00000 n 0000013351 00000 n 0000013737 00000 n 0000013834 00000 n … 5.�5�X�:�/��(.��{�ى-^��P��/_��)y����-����F�Yh�rE�b~槈�6���1�5�ݻ�(��]\��� �rFP`�) ��p�x���ʺ2��1Q�� aV4���ag�x/���=H���8�d�i��0���� Ot0V�%9n2.��0R �I�����]8����ש�&���MU����rDy ���W��A��C���5a*��ys쯱�T� ��j֛��$ ���)jsp �� �̓��?�sW��O7 ��X�Z�" �3����sG��(R)8� ��vHFO�WB&:�3�|�:?1��^�2 n��v%�1�y6ؗA��̀% :P �V=�y� Q��?��{�/&�4;ݑ���Sֵ��;� �4QP�r��|*1����|W�o�=S?��?@O�s���-����1�TtX�c�.au$ڵN ��QnɁ��_�o�* H��;j��}��{#��{�*��@� Eٷ�X?p �{c�hG�I��İ���w�����G�?{
News - Elixirgen Home Our Technology Pipeline News About Contact Menu We use cookies to improve usability. Privacy Statement Accept We use cookies to improve usability. Privacy Statement Accept --> Latest News All FDA Corporate Grants and Funding License Agreements R&D Clinical Trials --> 01.04.2023 Elixirgen Therapeutics to Attend the 2023 Biotech Showcase Conference --> 12.21.2022 Elixirgen Therapeutics Appoints Jeffrey L. Cleland, Ph.D., to Board of Directors --> 12.12.2022 Elixirgen Therapeutics Presents New Clinical Data Demonstrating Ex Vivo Telomere Elongation with EXG-34217 in Dysk
> Elixirgen Therapeutics Publishes Early Results Showing - GlobeNewswire >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #healthcare #biotech #pharmaceutical #competitivemarketing"> > Elixirgen Therapeutics Publishes Early Results Showing - GlobeNewswire >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #healthcare #biotech #pharmaceutical #competitivemarketing"> > Elixirgen Therapeutics Publishes Early Results Showing - GlobeNewswire >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #mark
News • Page 4 of 5 • Elixirgen Therapeutics Skip to content Science Clinical Trial About News Contact News & Media 26th January 2023 Elixirgen Therapeutics Enters Memorandum of Understanding with Hitachi Global Life Solutions for the Development of Micro GMP Suites for Cell Therapy Administration 5th January 2023 Elixirgen Therapeutics to Attend the 2023 Biotech Showcase Conference 21st December 2022 Elixirgen Therapeutics Appoints Jeffrey L. Cleland, Ph.D., to Board of Directors 12th December 2022 Elixirgen Therapeutics Presents New Clinical Data Demonstrating Ex Vivo Telomere Elo
Elixirgen Therapeutics Announces Licensing Agreement for Its Novel COVID-19 Vaccine Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Vide … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
SCGE Platform - Gene Therapy Clinical Trials × 👋 Hi there! I'm your AI assistant. Ask me anything about clinical trials, FDA documents! Contact SCGE Your email Message Send SCGE Consortium Home About SCGE TCDC Contact Us License Home Initiatives Therapeutic Leads Multiple Disease Platforms Platform Clinical Programs Regulatory Documents Gene Therapy Trial Browser All Trials Active Trials Recruiting Completed Trials Phase I Phase II Phase III IND Templates Phase 2 Publications Clinical Trials - Gene Therapy Trial Browser The Gene Therapy Trial Browser represents a unique pu … Or parasitic infection other protocol defined inclusion/exclusion criteria may apply">Key inclusion criteria: diagnosis of severe sickl... api Sickle Cell Disease Editas Medicine, Inc. Active not recruiting Ended development of this program due to inability to locate financial partner NCT02161380 Show Changes 2026-06-18 Eligibility criteria null 5.0 x upper limit of normal (uln); total bilirubin \>3 x uln; hemoglobin \ Inclusion criteria: 1. age 15 or older; 2. patien... api … assay with total anti-aav10 antibody titers of \>1:100. this criterion will not apply to children screened before they have received hsct or for children who sign the inform consent within 6 months from hsct. in children who test positive to anti-aav10 antibody with titers of \>1:100 under this exception, The isr regime proposed by the pi and approved/modified by the isr committee may include immunosuppressive drugs that prevent the potential development of a secondary immune … rgy to gadolinium note: other protocol defined inclusion/exclusion criteria may apply.">Inclusion criteria: * male and female 35-75 years... api Multiple System Atrophy Brain Neurotherapy Bio, Inc. Active not recruiting Phase 1 enrollment completed September 2025, this drug is also being evaluated for Parkinson's Disease indications NCT04124042 Show Changes 2026-06-18 Route of administration Intraarticular Intra-articular curator Delivery system None (naked plasmid) curator D … a syndrome at screening other protocol defined inclusion/exclusion criteria may apply.">Key inclusion criteria: * participants with tdt a... api Beta-Thalassemia, Sickle Cell Disease Vertex Pharmaceuticals Incorporated Recruiting FDA approved 12/8/23, price/treatment $2.2M, expanded indication to beta thalassemia 1/16/24 NCT05541627 Show Changes
Healthcare Private Placement and M&A Transactions Review Week Ending November 16, 2025 | Silverwood Partners About Us Overview Why Silverwood? Careers Our Location Connect With Us Insights & Analysis Newsletters Intelligence Briefs Events Connect With Us Team All Team Technology Consumer Healthcare Industry Experience Technology Consumer Healthcare Connect With Us Services Mergers & Acquisitions Private Placements Connect With Us Transactions All Transactions Technology Consumer Healthcare Connect With Us Healthcare Private Placement and M&A Transactions Review Week Ending N … : The company was acquired by Agon Electronics, via its financial sponsor Argos Fund, through an LBO on November 13, 2025 for an undisclosed amount. The company is a manufacturer of medical devices and provides contract assembly services for healthcare product development and commercialization. Doppl / InSphero: The company reached a definitive agreement to be acquired by InSphero for an undisclosed amount on November 11, 2025. The company is a developer of three-dimensional
Skip to main content MedPath Trial Home Trials Products Organizations News Research Pricing Search 中 Login Data Sources: ClinicalTrials.gov EU CTR FDA EMA NMPA TGA Health Canada WHO ICTRP MedPath Trial Home Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research. Product Clinical Trials Drug Intelligence Global Approvals AI Research Pricing Resources FAQ Search Company News About Contact Legal Privacy Policy Terms of Service Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medica … tion can lead to a Priority Review Voucher (PRV) upon approval of the marketing application for EXG-34217 Search drug , potentially accelerating the review of future applications. Executive Perspective "We’re pleased with the FDA’s decision to grant EXG-34217 Search drug RPDD for the treatment of DC/TBD, a rare group of diseases that result in abnormally short telomeres that can lead to bone marrow failure and other serious health conditions,” said Aki Ko, chief executiv
Shauna Callahan • Elixirgen Therapeutics Skip to content Science Clinical Trial About News Contact Shauna Callahan March 31, 2025 Shauna Callahan, CPA has served as a director for the company since March 2020. From 2019 to present, Ms. Callahan serves as the Chief Financial Officer for CampMinder, LLC. Ms. Callahan also serves as a director for Anchor Center for Blind Children. Her experience has centered around providing financial expertise and diligence to mid-sized businesses navigating high growth both organically and by acquisition. Ms. Callahan started her career in public accounting at
Elixirgen Therapeutics Cap Table & Ownership Structure 2026 Exchange Companies Investors Rankings More Toggle theme Companies Elixirgen Therapeutics Elixirgen Therapeutics Website Watch & Get Alerts Overview Valuation Cap Table Team Investors 2 Share Classes 0 Total Shares - Liquidation Pref N/A Current Valuation $67M Cap Table Data Not Available Detailed capitalization data has not been imported for Elixirgen Therapeutics yet. Contact us to request this information. Liquidation Waterfall Calculator Model exit scenarios and see how proceeds are distributed across share classes Try Calc
ELIXIRGEN THERAPEUTICS, INC. - Executive Bio, Top Executies, and Transitions - Equilar ExecAtlas Request a Demo Engage Executives. Unlock Deals. ExecAtlas delivers real-time insight into who-knows-who, paving the way for warm introductions that create opportunities. Search for an Executive Trusted by Industry Leaders Trusted by Industry Leaders Featured Organization ELIXIRGEN THERAPEUTICS, INC. elixirgentx.com Company Details Description Elixirgen Therapeutics is a biotechnology company focused on curing humanity’s ailments through stem cell biology. The company concentrates on regenerative an … rejuvenative medicine and deals with research in both basic science and in the application of the technologies it discovers and refines. Elixirgen Therapeutics is located in the Science + Technology Park at Johns Hopkins in Baltimore, an ideal research environment that allows Elixirgen Therapeutics’ scientists to conduct research at state-of-the-art facilities. Elixirgen Therapeutics inherits all the therapy-related assets, including intellectual property, from its parent co … rejuvenative medicine and deals with research in both basic science and in the application of the technologies it discovers and refines. Elixirgen Therapeutics is located in the Science + Technology Park at Johns Hopkins in Baltimore, an ideal research environment that allows Elixirgen Therapeutics’ scientists to conduct research at state-of-the-art facilities. Elixirgen Therapeutics inherits all the therapy-related assets, including intellectual property, from its parent co
Joel Rogers, CPA • Elixirgen Therapeutics Skip to content Science Clinical Trial About News Contact Joel Rogers, CPA March 31, 2025 Joel D. Rogers, CPA has served as Chief Financial Officer since December 2019. Mr. Rogers previously worked at Osiris Therapeutics, Inc. (NASDAQ: OSIR), which was acquired by Smith & Nephew in April 2019, as Chief Financial Officer from May 2018 to October 2019 and Corporate Controller from October 2017 to May 2018. Mr. Rogers served as Corporate Controller at ARC Group Worldwide, Inc. (NASDAQ: ARCW) from August 2014 to October 2017. Prior to ARC Group Worldwi
Elixirgen Therapeutics Announces Licensing Agreement for Its Novel COVID-19 Vaccine 27 June, 2026 | Saturday BioPharma America BioPharma Europe BioPharma Middle East BioPharma Africa BioPharma APAC Events Media Pack Login BioPharma Pharma & Biopharma Manufacturing Pharma Research Pharma QC Clinical Trials Drug Discovery Drug Approval BioSimilar Pharma Packaging LAB LAB Business LAB Health & Safety LAB Products LAB Design LAB Testing
Elixirgen Therapeutics Announces Licensing Agreement for Its Novel COVID-19 Vaccine • Elixirgen Therapeutics Skip to content Science Clinical Trial About News Contact Elixirgen Therapeutics Announces Licensing Agreement for Its Novel COVID-19 Vaccine October 8, 2021 BALTIMORE, Oct. 8, 2021 — Elixirgen Therapeutics, Inc., a Baltimore-based biotechnology company focused on the discovery and development of therapies for genetic diseases and vaccines, today announced it has entered into an exclusive licensing agreement with a global pharmaceutical company (currently undisclosed) for th
Elixirgen Therapeutics Partners with Taisho Pharmaceutical on Therapeutics for Aging-Associated Diseases • Elixirgen Therapeutics Skip to content Science Clinical Trial About News Contact Elixirgen Therapeutics Partners with Taisho Pharmaceutical on Therapeutics for Aging-Associated Diseases March 7, 2022 BALTIMORE, March 7, 2022 — Elixirgen Therapeutics, Inc., a Baltimore-based platform biotechnology company focused on the discovery and development of therapies for genetic diseases and vaccines, announced today that it has entered into an exclusive three-year research collaboratio
Elixirgen Therapeutics Presents New Clinical Data Demonstrating Ex Vivo Telomere Elongation with EXG-34217 in Dyskeratosis Congenita at the 64th ASH Annual Meeting • Elixirgen Therapeutics Skip to content Science Clinical Trial About News Contact Elixirgen Therapeutics Presents New Clinical Data Demonstrating Ex Vivo Telomere Elongation with EXG-34217 in Dyskeratosis Congenita at the 64th ASH Annual Meeting December 12, 2022 Elixirgen Therapeutics Presents New Clinical Data Demonstrating Ex Vivo Telomere Elongation with EXG-34217 in Dyskeratosis Congenita at the 64th ASH Annual Meeting T
Nippon Shinyaku and Elixirgen Therapeutics Enter Option Agreement for Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Release … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Elixirgen Therapeutics Presents Preclinical Data with Bobcat mRNATM Technology in Duchenne Muscular Dystrophy at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference • Elixirgen Therapeutics Skip to content Science Clinical Trial About News Contact Elixirgen Therapeutics Presents Preclinical Data with Bobcat mRNATM Technology in Duchenne Muscular Dystrophy at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference March 4, 2024 Bobcat mRNA TM technology is a novel linear mRNA platform able to encode large proteins Data showed resto
Elixirgen Therapeutics Appoints Jeffrey L. Cleland, Ph.D., to Board of Directors | BioBuzz All Regions All Regions BioHealth Capital Region Greater Philadelphia Research Triangle Park News Events BioCatalyst Program Sign Up Elixirgen Therapeutics Appoints Jeffrey L. Cleland, Ph.D., to Board of Directors By Cat Thoreson · Published July 16, 2025 · 3 min read ← News / Elixirgen Therapeutics Appoints Jeffrey L. Cleland, Ph.D., to… Elixirgen Therapeutics Appoints Jeffrey L. Cleland, Ph.D., to Board of Directors GlobeNewswire BALTIMORE, Dec. 21, 2022 (GLOBE NEWSWIRE) — Elix … cribe Related Articles Funding Press Release OTraces Awarded $2 Million Florida Grant to Advance Non‐Invasive, High‐Accuracy Prostate Cancer Detection June 26, 2026 People 5 Questions With 5 Questions With Chidiebube Chikezie June 25, 2026 Press Release Minaris Enhances GMP Cell Banking Capabilities at Philadelphia Facility June 24, 2026 Explore News Events Resources & Tools Company About Us Team History Contact © 2026 BioBuzz Networks. All rights reserved. Privacy P
Developing an mRNA Therapy for DMD with Elixirgen Therapeutics Aki Ko Get more Cell & Gene insight with our FREE newsletter sign me up Log In or Subscribe Explore CGT Production Vectors Cell Therapy Manufacturing Gene Therapy Manufacturing Formulation Fill-Finish Cold Chain Management Quality Control & Assurance Find Suppliers Clinical Trial Services Manufacturing Regulatory Supply Chain Outsourcing Translational Research Watch Now STREAM Video Channel Cell & Gene Live Cell & Gene: The Podcast Cell & Gene Tech Expo Our Communities Advancing RNA Bioprocess Online Clinical Le … specific interests: Job Title Company What topics interest you? (Check all that apply.) Clinical Trials Manufacturing Outsourcing Regulatory & Compliance Supply Chain Translational Research Save and Access Content Newsletter Signup I agree to the Terms . I consent to the processing of my personal data for follow-up and B2B marketing communications by Life Science Connect and our trusted sponsors/clients in the life sciences industry. Data Controller: Life Science Connect,
News • Elixirgen Therapeutics Skip to content Science Clinical Trial About News Contact News & Media 26th June 2026 Elixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy 25th February 2025 Elixirgen Therapeutics Publishes Early Results Showing Telomere Elongation in First Gene Therapy Trial for Telomere Biology Disorders 20th February 2025 Elixirgen Therapeutics Granted FDA Orphan Drug Designation for EXG-34217 for Treatment of Telomere Biology Disorders 13th February 2025 Elixirgen
Elixirgen Therapeutics Funding: How Much Did They Raise & Key Investors Products Product ZoomInfo Copilot AI sales agent GTM Workspace AI workspace for smarter GTM GTM Studio Build and run GTM workflows triggered by buying signals ZoomInfo MCP Connect your AI to verified B2B data Sales Company and contact database Marketing Actionable ABM platform Talent Source the best and brightest Operations Lead routing and data quality Data as a Service ZoomInfo data for your GTM systems Platform Cloud partners Ready, set, integrate Platform overview Connect industry-leading data across your entire te
Nippon Shinyaku and Elixirgen Therapeutics Enter Option Agreement for Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy Something went wrong Skip to navigation Skip to main content Skip to right column Yahoo Finance News Finance More News Today's news Singapore Politics Southeast Asia World Sports Personal Finance Property Weather Lifestyle Travel Health Fashion Celebrity Parenting Food Finance My portfolio Markets Watchlists Screeners Money News Cryptocurrencies Industries Property Sign in My Portfolio News Stocks Singapore Economics Property Tech Crypto Currencies
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Elixirgen’s gene therapy shows promise in telomere biology disorders Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Categories Product … Chain Data Management Medical Devices Latest Ollin Biosciences secures $330m to fund Phase III OLN324 trials Viking Therapeutics commences Phase I trial of VK3019 Ascletis receives FDA clearance for Phase I trial of obesity treatment Themes Sections Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Foreign Direct Investment Latest How wearables can unlock their full potentia
Elixirgen Therapeutics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EXG-34217 for Treatment of Telomere Biology Disorders - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FD … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Elixirgen Therapeutics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EXG-34217 for Treatment of Telomere Biology Disorders February 14, 2025 | 2 min read Twitter LinkedIn Facebook Email Print BALTIMORE, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc., a clinical- … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Elixirgen Therapeutics Skip to content Science Clinical Trial About News Contact We develop life-changing therapies, focusing on rare diseases and aging-associated diseases using our cutting-edge technologies. Science About Reimagining Patient-Centric Medicine ZSCAN4 and Telomere Biology Disorders Our ZSCAN4 technology is currently in clinical trials to extend telomeres in patients with Telomere Biology Disorders, a rare disease with significant unmet need. Bobcat® mRNA Our Bobcat® mRNA technology uses a proprietary mRNA design to deliver large payloads such as full-length dystrophin, which is
Elixirgen Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 05 Mar 2026 Elixirgen Therapeutics, Inc. Startups | Holding Company | 2017 | Maryland, United States | 10-50 | elixirgentx.com Startups | Holding Company | 2017 | Maryland, United States | 10-50 | elixirgentx.com Last update 05 Mar 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Respiratory Diseases Infectious Diseases Other Diseases Prophylactic vaccine saRNA vaccine mRNA Di … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Elixirgen Therapeutics | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies Elixirgen Therapeutics Elixirgen Therapeutics is a clinical-stage biotechnology company focused on curing humanity’s ailments through innovations in cell and gene therapy, vaccine development, and platform technologies such as ZSCAN4 and controllable self-replicating RNA (c-srRNA). The company is dedicated to developing therapies for rare diseases, aging-associated diseases, and infectious diseases like COVID-19, leveraging proprietary technologies and c
Elixirgen Therapeutics Publishes Early Results Showing Telomere Elongation in First Gene Therapy Trial for Telomere Biology Disorders • Elixirgen Therapeutics Skip to content Science Clinical Trial About News Contact Elixirgen Therapeutics Publishes Early Results Showing Telomere Elongation in First Gene Therapy Trial for Telomere Biology Disorders February 25, 2025 Data published in NEJM Evidence detail the first clinical test of ZSCAN4 for telomere elongation. Treatment with EXG-34217 resulted in in vivo telomere elongation in a subpopulation of lymphocytes to the normal range for age
Elixirgen Therapeutics Receives Rare Pediatric Disease Designation for EXG-34217 in Dyskeratosis Congenita and Related Telomere Biology Disorders • Elixirgen Therapeutics Skip to content Science Clinical Trial About News Contact Elixirgen Therapeutics Receives Rare Pediatric Disease Designation for EXG-34217 in Dyskeratosis Congenita and Related Telomere Biology Disorders September 25, 2024 Elixirgen Therapeutics is currently enrolling patients in its Phase 1/2 trial evaluating EXG-34217 in patients with telomere biology disorders at Cincinnati Children’s Hospital Medical Center BALTIMOR … or a Phase 1/2 trial ( NCT04211714 ). “We’re pleased with the FDA’s decision to grant EXG-34217 RPDD for the treatment of DC/TBD, a rare group of diseases that result in abnormally short telomeres that can lead to bone marrow failure and other serious health conditions,” said Aki Ko, chief executive officer of Elixirgen Therapeutics. “The RPDD is a recognition of the significant unmet need in this space and the potential of EXG-34217, and we look forward to working with the F … States and primarily affect patients less than 18 years of age. If a marketing application for EXG-34217 for the treatment of DC/TBDs is approved by the FDA, Elixirgen Therapeutics may be eligible to receive a Priority Review Voucher (PRV) that could be used to receive accelerated review of any subsequent application. About Elixirgen Therapeutics, Inc. Elixirgen Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commerciali
Elixirgen Therapeutics Skip to content Science Clinical Trial About News Contact We develop life-changing therapies, focusing on rare diseases and aging-associated diseases using our cutting-edge technologies. Science About Reimagining Patient-Centric Medicine ZSCAN4 and Telomere Biology Disorders Our ZSCAN4 technology is currently in clinical trials to extend telomeres in patients with Telomere Biology Disorders, a rare disease with significant unmet need. Bobcat® mRNA Our Bobcat® mRNA technology uses a proprietary mRNA design to deliver large payloads such as full-length dystrophin, which is
Setting the Stage for ASH 2022 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases P … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Setting the Stage for ASH 2022 December 9, 2022 | 6 min read | Rosemary Scott and Heather McKenzie Twitter LinkedIn Facebook Email Print At ASH 2022, established hematology leaders like AstraZeneca, Janssen and Merck will showcase new data, and new players like Vega Thera … w company has secured Austrian Competent Authority approval of a clinical trial application for a Phase I study in VWD. Vega CEO and Co-founder Adam Rosenthal, Ph.D. said drug innovation for VWD has lagged. “At Vega, we see a future where we can better meet the needs of patients by advancing VGA039 as the first purpose-built antibody therapy for VWD,” he said in a statement Tuesday. Vega is supported by $40 million in financing from Star and several other investors including … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Elixirgen Therapeutics Presents New Clinical Data Demonstrating Ex Vivo Telomere Elongation with EXG-34217 in Dyskeratosis Congenita at the 64th ASH Annual Meeting - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug D … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Elixirgen Therapeutics Presents New Clinical Data Demonstrating Ex Vivo Telomere Elongation with EXG-34217 in Dyskeratosis Congenita at the 64th ASH Annual Meeting December 12, 2022 | 4 min read Twitter LinkedIn Facebook Email Print Elixirgen Therapeutics, Inc. today announced new dat … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
FDA Approves Elixirgen Therapeutics IND Application for Therapy for Telomere Biology Disorders with Bone Marrow Failure - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News FDA FDA Approves Elixirgen Therapeutics IND Application for Therapy for Telomere Biology Disorders with Bone Marrow Failure June 4, 2020 | 2 min read Twitter LinkedIn Facebook Email Print Elixirgen Therapeutics, Inc., a Baltimore -based biotechnology company focused on the discovery, development, and … U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) application for its lead candidate, EXG34217, wa BALTIMORE , June 4, 2020 /PRNewswire/ -- Elixirgen Therapeutics, Inc. , a Baltimore -based biotechnology company focused on the discovery, development, and commercialization of therapies for genetic diseases and vaccines, received confirmation from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) application … http://www.prnewswire.com/news-releases/fda-approves-elixirgen-therapeutics-ind-application-for-therapy-for-telomere-biology-disorders-with-bone-marrow-failure-301070733.html SOURCE Elixirgen Therapeutics Twitter LinkedIn Facebook Email Print FDA Approvals LATEST Cancer Replimune gets early August decision date for twice-rejected melanoma drug June 26, 2026 · 3 min read · Tristan Manalac IPO BIO 2026: Making biotech IPOs great again an … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Elixirgen Therapeutics Presents Preclinical Data with Bobcat mRNATM Technology in Duchenne Muscular Dystrophy at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu S … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BioCapital Elixirgen Therapeutics Presents Preclinical Data with Bobcat mRNATM Technology in Duchenne Muscular Dystrophy at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference March 4, 2024 | 2 min read Twitter LinkedIn Facebook Email Print Elixirgen Therapeutics, Inc., today presented pre … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kinder-and-gentler-join-biospace-at-bio-to-find-out" > Antibody-drug conjugate Can ADCs be kinder and gentler? Join BioSpace at BIO to find out June 23, 2026 ·&n … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Elixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Devel … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Elixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy June 26, 2026 | 2 min read Twitter LinkedIn Facebook Email Print BALTIMORE, June 26, 2026 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc ., a cli … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Empowered Patient Podcast: Using Self-Replicating RNA Technology to Treat Telomere Biology Disorders with Akihiro Ko Elixirgen Therapeutics TRANSCRIPT Toggle navigation About Contact Episodes All Episodes Categories Addiction Aging and Seniors Allergies Big Data Big Data and AI Cancer Cardiology CBD Cell Therapy Central Nervous System Clinical AI Clinical Trials COVID-19 Depression Dermatology Diabetes Diagnostics Dietary Supplements Digital Health Doctors Empowering Patients Epigenetics Gastrointestinal Disorders general Gene Therapy Genetics GIS Healthcare Investing Healthcare Protesting Hea … ith Karen Jagoda is a window into the latest innovations in digital health, the application of AI for administrative and clinical uses, the changing dynamic between doctors and patients, personalized medicine, cell and gene therapies, aging in place, wearables and sensors, clinical trials and advances in clinical research, payer trends, transparency in the medical marketplace and challenges for connected health entrepreneurs. This show continues to evolve driven by the conver
About - Elixirgen Home Our Technology Pipeline News About Contact Menu We use cookies to improve usability. Privacy Statement Accept We use cookies to improve usability. Privacy Statement Accept --> Elixirgen Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of therapies using its controllable RNA platform. About Elixirgen Therapeutics Elixirgen Therapeutics, Inc. is a Baltimore-based biotechnology company co-founded by Akihiro Ko and Minoru Ko, MD, PhD in 2017. The company is focused on the discovery, development, and com … People of Japan in 2013 by the Nikkei Business Magazine, and won the Semi-Grand Prize for Woman of the Year in 2014 by Nikkei. Hiroaki Kobayashi Board Member Hiroaki Kobayashi Board Member Hiroaki Kobayashi, MD, has served as a director of the company since February 2020. Dr. Kobayashi currently serves as a Venture Partner at University of Tokyo Edge Capital Company (UTEC), focusing on supporting companies in the life sciences and medical fields. Prior to UTEC, Dr. Kobayashi
Elixirgen Therapeutics, Inc.｜Our Companies｜UTEC-The University of Tokyo Edge Capital Partners Co., Ltd. UTEC UTEC’s Edge Network HR Support Expert Support Global Our Companies Story Our Team About Us Firm Profile Investment Policy Access News Compliance & Policies Recruit UTEC Recruit Venture Partner Recruit Startup Opportunity Club Contact Investment consultation Other Inquiries Podcast X Facebook Linkedin JP EN Our Companies HOME Our Companies --> Elixirgen Therapeutics, Inc. Chief Executive Officer： Akihiro Ko URL: https://elixirgentherapeutics.com/ COMPANY PROFILE Revolutionary cure fo … ssor at Keio University and formerly a Section Chief at the NIH. Dr Ko aimed to apply his discoveries in stem cell biology to cure diseases. Strength Elixirgen’s technology is based on the discovery that the ZSCAN4 gene increases the genome stability of the stem cell and elongates telomeres. The company developed the technology to introduce ZSCAN4 into cells such as hematopoietic stem cells in the form of RNA therapeutic agent that does not disrupt the genome, rendering the p … NT CATEGORY Life Science & Healthcare IT Physical Science & Engineering Fund FUND UTEC6 (2025 vintage) UTEC5 (2021 vintage) UTEC4 (2018 vintage) UTEC3 (2013 vintage) UTEC2 (2009 vintage) UTEC1 (2004 vintage) STORY LIST UTECが投資している方々やEXIT済み企業とのインタビューを掲載しています。 READ MORE READ MORE JP EN UTEC’s Edge Network HR Support Expert Support Global Our Companies Story Our Team About Us Firm Profile Investment Policy Access News Compliance & Policies Recruit UTEC Recruit Ventur
Elixirgen Therapeutics, Inc. raises $4 million in Series A funds • Elixirgen Therapeutics Skip to content Science Clinical Trial About News Contact Elixirgen Therapeutics, Inc. raises $4 million in Series A funds July 9, 2018 BALTIMORE, July 9, 2018 – Elixirgen Therapeutics, Inc. raised $4 million in a Series A funding round from University of Tokyo Edge Capital (UTEC) . Elixirgen Therapeutics, Inc. is a biotechnology company founded by Minoru Ko, M.D., Ph.D., that is focused on curing humanity’s ailments through innovations in stem cell biology. Elixirgen Therapeutics is pursuing cures … seases such as Dyskeratosis Congenita. The company is on track to filing an IND application and beginning clinical trials for its lead candidate in 2019. Elixirgen Therapeutics is pleased to begin a professional relationship with UTEC and is looking forward to working with the “co-founders for innovation.” The company will be counting on UTEC’s vast network of connections and their experience in improving businesses at all stages of development. With the help of UTEC, Elixirg
Developing an mRNA Therapy for… ‑ Cell & Gene: The Podcast ‑ Apple Podcasts Rechercher Accueil Nouveautés Classements Rechercher 6 juin 2024 15 min Developing an mRNA Therapy for DMD with Elixirgen Therapeutics' Aki Ko Cell & Gene: The Podcast Lire We love to hear from our listeners. Send us a message. Elixirgen Therapeutics' Aki Ko joins Erin Harris to detail the company's Bobcat mRNA therapeutic and how it differs from traditional exon-skipping drugs and AAV-microdystrophin in treating DMD. Regarding delivery, Ko explains the advantage of the mRNA approach over the AAV approach. Subs
Elixirgen Therapeutics’ Innovative Approach to mRNA Therapeutics - Xtalks Monday, June 29, 2026 | 11am EDT: Using Lessons from FinTech to Improve Clinical Trial Interoperability X Skip to content LOGIN JOIN Webinars Industries All Life Sciences Pharma Biotech Medtech Healthcare Research Food News & Features All Xtalks Editorial News Blogs Videos Quizzes & Polls Pharmaville Xtalks Spotlight Life Science Podcast Xtalks Clinical Edge™ Community Features Peer Circles Industry Jobs Search Jobs Post Job Talent Acquisition & Branding Bundle Partner With Us All Services Host a Webinar S … of your data Security We take precautions to protect your information. When you submit sensitive information on our Site, your information is protected both online and offline. We use encryption to protect sensitive information transmitted online and we protect your information offline. Only our employees who need your information to perform a specific task (for example, customer service or marketing) are granted access to personally identifiable information. The computers an … ing address, address, email address and telephone numbers. Resume Data includes application materials and answers to screener questions given to employers through the Xtalks Job Platform and answers to any questionnaires. This information may be associated with a profile. Transaction Data includes details about payments and other details of products and services bought from us. Technical Data includes internet protocol (IP) address, login data, browser type and version, time … on xtalks.com e.g., searches you run or webinars and jobs you click on when you apply to jobs or for webinars, use screener or assessment questions or log in from third party sites information we learn about you through our relationship and the way you interact with us In some circumstances we may also receive information from: regulatory bodies other companies supplying services to us data analytics to improve our website, products/services, marketing, customer relationships … imited circumstances, for example, repeated requests for further copies, we may apply an administration fee. Rectification of personal data – this right enables you to have any incomplete or inaccurate data we hold about you corrected, though we may need to verify the accuracy of the new data you provide to us. Erasure of personal data – Yo
Developing an mRNA Therapy for DMD with Elixirgen Therapeutics' Aki Ko - Cell & Gene: The Podcast | Podcast on Spotify
Developing an mRNA Therapy for… - Cell & Gene: The Podcast - Apple Podcasts Search Home New Top Charts Search June 6, 2024 15 min Developing an mRNA Therapy for DMD with Elixirgen Therapeutics' Aki Ko Cell & Gene: The Podcast Play We love to hear from our listeners. Send us a message. Elixirgen Therapeutics' Aki Ko joins Erin Harris to detail the company's Bobcat mRNA therapeutic and how it differs from traditional exon-skipping drugs and AAV-microdystrophin in treating DMD. Regarding delivery, Ko explains the advantage of the mRNA approach over the AAV approach. Subscribe to the podca
Developing an mRNA Therapy for DMD with Elixirgen Therapeutics Aki Ko Get more Cell & Gene insight with our FREE newsletter sign me up Log In or Subscribe Explore CGT Production Vectors Cell Therapy Manufacturing Gene Therapy Manufacturing Formulation Fill-Finish Cold Chain Management Quality Control & Assurance Find Suppliers Clinical Trial Services Manufacturing Regulatory Supply Chain Outsourcing Translational Research Watch Now STREAM Video Channel Cell & Gene Live Cell & Gene: The Podcast Cell & Gene Tech Expo Our Communities Advancing RNA Bioprocess Online Clinical Le … specific interests: Job Title Company What topics interest you? (Check all that apply.) Clinical Trials Manufacturing Outsourcing Regulatory & Compliance Supply Chain Translational Research Save and Access Content Newsletter Signup I agree to the Terms . I consent to the processing of my personal data for follow-up and B2B marketing communications by Life Science Connect and our trusted sponsors/clients in the life sciences industry. Data Controller: Life Science Connect,